1 BTC
=
- USD
Actinium Pharmaceuticals, Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Market Statistics
Trading Metrics
How to Buy ATNM
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ATNM
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe targeted alpha therapy market is experiencing rapid growth driven by advancements in alpha emitters like Actinium-225, Astatine-211, and Lead-212 across clinical stages. Over 30 drugs are in clinical trials, with promising results in treating metastatic and drug-resistant cancers including prostate cancer and hepatocellular carcinoma. Major pharmaceutical companies and emerging biotech firms are actively developing these therapies, with recent M&A activity including AstraZeneca's acquisition of Fusion Pharmaceuticals and Bristol Myers Squibb's acquisition of RayzeBio, positioning targeted alpha therapy as a future pillar of precision medicine.
A new market research report reveals targeted alpha therapies (TAT) for cancer treatment are projected to grow from $199.6 million in 2024 to $1.1 billion by 2030, with a 44% CAGR, driven by precision medicine and unmet oncology treatment needs.
Rosen Law Firm is encouraging investors in Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to seek legal counsel before the May 27 deadline for a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the likelihood of its Iomab-B drug candidate being approved by the FDA.
Rosen Law Firm is encouraging investors of Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to secure legal counsel before the May 27, 2025 deadline for a securities class action lawsuit.
A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making materially false and misleading statements about the likelihood of FDA approval for its drug Iomab-B.